GSK 568893A

Drug Profile

GSK 568893A

Alternative Names: GSK-568893A; Human papillomavirus (types 16, 18, 31, 45) L1 virus-like particle vaccine - GlaxoSmithKline; Human papillomavirus (types 16, 18, 31, 45) L1 VLP vaccine - GlaxoSmithKline; Human papillomavirus quadrivalent (types 16, 18, 31, 45) recombinant vaccine - GlaxoSmithKline; Tetravalent HPV L1 16/18/31/45 virus-like particle vaccine - GlaxoSmithKline

Latest Information Update: 12 May 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Cancer vaccines; Papillomavirus vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cervical cancer; Human papillomavirus infections

Most Recent Events

  • 12 May 2014 Discontinued - Phase-II for Cervical cancer in Belgium (IM)
  • 12 May 2014 Discontinued - Phase-II for Cervical cancer in USA (IM)
  • 12 May 2014 Discontinued - Phase-II for Human papillomavirus infections in Belgium (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top